Skip to main content
Erschienen in: Reactions Weekly 1/2015

01.05.2015 | Case report

Alectinib

ALK I1171 (I1171N/S) mutations leading to acquired resistance: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Ou S-HI, et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. Journal of Thoracic Oncology 9: 1821-1825, No. 12, Dec 2014. Available from: URL: http://doi.org/10.1097/JTO.0000000000000368 - USACrossRefPubMed Ou S-HI, et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. Journal of Thoracic Oncology 9: 1821-1825, No. 12, Dec 2014. Available from: URL: http://​doi.​org/​10.​1097/​JTO.​0000000000000368​ - USACrossRefPubMed
Metadaten
Titel
Alectinib
ALK I1171 (I1171N/S) mutations leading to acquired resistance: 2 case reports
Publikationsdatum
01.05.2015
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-1790-4

Weitere Artikel der Ausgabe 1/2015

Reactions Weekly 1/2015 Zur Ausgabe

Case report

Tocilizumab

Case report

Mineral oil

Case report

Imatinib